CBS 2019
CBSMD教育中心
中 文

Scientific Library

Abstract

Recommended Article

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced Diagnosis of ischemia-causing coronary stenoses by noninvasive fractional flow reserve computed from coronary computed tomographic angiograms. Results from the prospective multicenter DISCOVER-FLOW A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation Clinical epidemiology of heart failure with preserved ejection fraction (HFpEF) in comparatively young hospitalized patients Atrial Fibrillation and the Prognostic Performance of Biomarkers in Heart Failure Long-Term Durability of Transcatheter Heart Valves: Insights From Bench Testing to 25 Years Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

Original Research2018;7:e009806

JOURNAL:JAHA Article Link

Guideline‐Directed Medical Therapy for Patients With Heart Failure With Midrange Ejection Fraction: A Patient‐Pooled Analysis From the KorHF and KorAHF Registries

Ki Hong Choi Jin‐Oh Choi et al. Keywords: heart failure with midrange ejection fraction; HFmrEF; acute HF; β‐blocker; renin‐angiotensin system blocker; all‐cause mortality

FULL TEXT PDF